10x Genomics (NASDAQ:TXG) Director Sells $1,155,000.00 in Stock

Posted by George Bondi on Aug 16th, 2026

10x Genomics (NASDAQ:TXG – Get Free Report) Director John Stuelpnagel sold 20,000 shares of 10x Genomics stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $57.75, for a total value of $1,155,000.00. Following the completion of the transaction, the director owned 348,436 shares of the company’s stock, valued at $20,122,179. The trade was a 5.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

10x Genomics Stock Performance

TXG stock opened at $56.09 on Friday. The company’s 50 day moving average price is $41.93 and its 200 day moving average price is $28.87. 10x Genomics has a fifty-two week low of $11.16 and a fifty-two week high of $60.69. The firm has a market capitalization of $7.12 billion, a price-to-earnings ratio of -95.07 and a beta of 2.03.

10x Genomics (NASDAQ:TXG – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.10. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The company had revenue of $151.04 million during the quarter, compared to the consensus estimate of $146.67 million. During the same quarter in the previous year, the firm earned $0.28 earnings per share. The firm’s quarterly revenue was down 12.7% on a year-over-year basis. Equities analysts forecast that 10x Genomics will post -0.79 EPS for the current fiscal year.

Analysts Set New Price Targets

TXG has been the topic of several recent research reports. Zacks Research cut shares of 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 18th. Barclays raised their target price on shares of 10x Genomics from $30.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Canaccord Genuity Group lifted their target price on shares of 10x Genomics from $50.00 to $60.00 and gave the company a “buy” rating in a report on Monday, August 10th. Morgan Stanley boosted their price target on shares of 10x Genomics from $37.00 to $40.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 10x Genomics in a report on Wednesday, June 24th. Five research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, 10x Genomics currently has an average rating of “Hold” and a consensus target price of $38.31.

Read Our Latest Research Report on TXG

Institutional Trading of 10x Genomics

Several hedge funds and other institutional investors have recently made changes to their positions in TXG. Intech Investment Management LLC grew its position in 10x Genomics by 1.4% during the fourth quarter. Intech Investment Management LLC now owns 40,047 shares of the company’s stock worth $653,000 after buying an additional 567 shares during the period. Certuity LLC increased its holdings in 10x Genomics by 4.7% in the fourth quarter. Certuity LLC now owns 20,204 shares of the company’s stock valued at $330,000 after buying an additional 904 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of 10x Genomics by 16.4% during the 1st quarter. EverSource Wealth Advisors LLC now owns 7,186 shares of the company’s stock valued at $153,000 after acquiring an additional 1,012 shares during the period. Kera Capital Partners Inc. lifted its position in shares of 10x Genomics by 2.3% during the 1st quarter. Kera Capital Partners Inc. now owns 48,937 shares of the company’s stock valued at $1,039,000 after acquiring an additional 1,108 shares during the period. Finally, Elevation Wealth Partners LLC boosted its stake in shares of 10x Genomics by 332.3% during the 2nd quarter. Elevation Wealth Partners LLC now owns 1,487 shares of the company’s stock worth $57,000 after acquiring an additional 1,143 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Company Profile

(Get Free Report)

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.